AxoGen, Inc.

AXGN Healthcare Medical Devices

AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.

Revenue
+26.2%
EPS
+163.2%
Free cash flow
+995.0%
Total debt
−73.1%

Quarter to September 2026, against a year earlier

50.00 1.25 +2.56%
Market cap
$2.9B
P/E
0.0×
Fwd P/E
−129×
Dividend yield
—
F-score
5/9
Altman Z
9.23
Beneish M
−2.73
Dividend safety
n/a

AxoGen, Inc. (AXGN) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, AxoGen, Inc. (AXGN) trades at a EV/Sales of 8.8×. Over the past ten years it has ranged from 1.2× (November 2023) to 27.6× (June 2018); the current reading is higher than 84% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.8× 67.70%
FY2024 4.0× 96.24%
FY2023 2.1× (33.21%)
FY2022 3.1× 8.31%
FY2021 2.9× (51.34%)
FY2020 5.9× 3.79%
FY2019 5.6× (25.46%)
FY2018 7.6× (50.21%)
FY2017 15.2× 133.81%
FY2016 6.5× 37.71%

Quarterly newest first

Period EV/Sales Change
Sep 2026 7.4× (21.33%)
Jun 2026 9.4× 38.18%
Mar 2026 6.8× 0.58%
Dec 2025 6.8× 70.06%
43 more quarters

Against its own ten years

Low 1.2× High 27.6×
Ten-year median 4.8×
Current reading's percentile 82

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AXGN